Moderna, Inc. (BVL:MRNAUS)
Peru · Delayed Price · Currency is PEN · Price in USD | Market Cap | 92.10B +148.6% |
| Revenue (ttm) | 7.77B -30.0% |
| Net Income | -11.15B |
| EPS | -28.50 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 81.80 |
| Day's Range | n/a |
| 52-Week Range | 27.29 - 81.80 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 31, 2026 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provid... [Read more]
Financial Performance
In 2025, Moderna's revenue was $1.94 billion, a decrease of -39.93% compared to the previous year's $3.24 billion. Losses were -$2.82 billion, -20.75% less than in 2024.
Financial numbers in USD Financial StatementsNews
Here’s Why Moderna Stock (MRNA) Is Crashing Today — July 10, 2026
Shares in Moderna ($MRNA) tumbled by 12% on Friday afternoon after JPMorgan ($JPM) reaffirmed its Sell rating on the U.S. pharma and biotech company. The banking giant also listed Moderna…
Moderna wins EU contract for RSV vaccine supply
Moderna said on Thursday it has secured a European Commission contract to supply its respiratory syncytial virus vaccine to six countries in the region.
Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
CAMBRIDGE, MA / ACCESS Newswire / July 9, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, July 31, 2026 to report it...
Moderna price target raised to $39 from $33 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Moderna (MRNA) to $39 from $33 and keeps an Equal Weight rating on the shares. Biotech could benefit from broader market leadership…
Moderna appoints Michael McDonnell to Board of Directors
Moderna (MRNA) appointed Michael McDonnell to its Board of Directors, effective July 8. McDonnell will also serve on the Board’s Audit Committee. Most recently, McDonnell served as EVP and CFO…
Moderna Appoints Michael McDonnell to Board of Directors
Former Biogen Chief Financial Officer brings more than 35 years of financial leadership and public company experience CAMBRIDGE, MA / ACCESS Newswire / July 8, 2026 / Moderna, Inc. (NASDAQ:MRNA) today...
Moderna price target raised to $38 from $34 at BofA
BofA raised the firm’s price target on Moderna (MRNA) to $38 from $34 and keeps an Underperform rating on the shares. Limited surprises are expected from the Q2 print given…
Moderna price target raised to $45 from $38 at RBC Capital
RBC Capital raised the firm’s price target on Moderna (MRNA) to $45 from $38 and keeps a Sector Perform rating on the shares as part of a broader research note…
Moderna stock jumps as pipeline progress and flu shot data lift sentiment
Moderna Inc. (MRNA) shares rose 9.2% on Thursday, making the biotechnology company among the top performers in the S&P 500 as investors responded positively to new pipeline updates, encouraging influe...
Jim Cramer says this former Covid market darling is finally investable again
CNBC's Jim Cramer said Moderna has evolved beyond its Covid-era business, arguing the biotech company's expanding pipeline in treatments for cancer and other diseases provides a compelling long-term i...
Moderna stock soars as cancer pipeline and CAR-T push ignite optimism
Moderna Inc. (MRNA) shares surged nearly 10% on Friday, extending a powerful rally that has lifted the stock about 40% over the past month and significantly outperformed the broader market. The gains ...
Why Moderna (MRNA) Stock Is Soaring Today – June 26, 2026
Moderna ($MRNA) stock jumped nearly 15% at one point on Friday to around $69 per share after investors reacted positively to the biotech firm’s latest Science Day update. The move…
Why Moderna Stock Is Soaring and Leading the S&P 500 Today
Moderna shares pace toward their highest close since late 2024 after unveiling a new cell therapy program.
Moderna price target raised to $77 from $69 at Piper Sandler
Piper Sandler raised the firm’s price target on Moderna (MRNA) to $77 from $69 and keeps an Overweight rating on the shares.
Moderna Transcript: Science Day 2026
The event outlined a robust pipeline expansion across oncology, autoimmune, and infectious diseases, driven by platform innovation, AI, and multiplexing strategies. Key clinical programs are advancing, with financial guidance unchanged and commercialization plans to be tailored post-proof-of-concept.
Moderna Slides: FY 2026
Moderna has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 25, 2026.
Moderna Science Day highlights potential of mRNA platform
Moderna (MRNA) announced research and early development updates at its Science Day event. Moderna is executing a strategy that balances near-term growth with long-term innovation. Building on the mome...
Moderna Science Day Highlights Expanding Potential of mRNA Platform
Provides broad overview of Company's research and early development programs expected to continue to fuel future growth Highlights validation of T-cell engager modality with mRNA-2808 in multiple myel...
FDA Votes in Favor of Benefit-Risk Profile for Moderna's Flu Vaccine
Moderna said the FDA's Vaccines and Related Biological Products Advisory Committee voted unanimously that the benefits of the vaccine, mRNA-1010, exceed the risks for the prevention of flu in adults 5...